Vontobel Holding’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$72.8K Hold
35,000
﹤0.01% 1430
2026
Q1
$85.4K Sell
35,000
-27,080
-44% -$54.3K ﹤0.01% 1155
2025
Q4
$85K Hold
62,080
﹤0.01% 1377
2025
Q3
$77K Buy
62,080
+28,080
+83% +$33.5K ﹤0.01% 1303
2025
Q2
$38.4K Sell
34,000
-151,646
-82% -$202K ﹤0.01% 1242
2025
Q1
$271K Sell
185,646
-9,811
-5% -$18.5K ﹤0.01% 925
2024
Q4
$416K Buy
195,457
+173,457
+788% +$428K ﹤0.01% 840
2024
Q3
$61.6K Hold
22,000
﹤0.01% 1053
2024
Q2
$51.3K Buy
22,000
+4,000
+22% +$11.8K ﹤0.01% 1040
2024
Q1
$80.5K Hold
18,000
﹤0.01% 1035
2023
Q4
$57.8K Buy
18,000
+4,000
+29% +$11.3K ﹤0.01% 1065
2023
Q3
$44.4K Hold
14,000
﹤0.01% 1045
2023
Q2
$69.6K Sell
14,000
-10,000
-42% -$54.1K ﹤0.01% 1063
2023
Q1
$119K Hold
24,000
﹤0.01% 1018
2022
Q4
$151K Sell
24,000
-89,711
-79% -$831K ﹤0.01% 1014
2022
Q3
$1.23M Buy
113,711
+4,067
+4% +$55.3K 0.01% 502
2022
Q2
$1.25M Buy
+109,644
New +$973K 0.01% 490

Other funds holding ALLO

Vontobel Holding's ALLO Position: Q2 2026 in Review

Vontobel Holding held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 35,000 shares worth $72.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1430.

Vontobel Holding first reported a position in ALLO in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.25M in Q2 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vontobel Holding held 35,000 shares of Allogene Therapeutics worth $72.8K as of Q2 2026.
  • Vontobel Holding left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q2 2026, its #1430 holding.
  • Vontobel Holding first reported a position in Allogene Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Vontobel Holding's Allogene Therapeutics position peaked at $1.25M in Q2 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.